Yazar "Kars, Taha Ulutan" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The Long-Term Analysis of Hematological Malignancies: Patients with COVID-19 versus without COVID-19(Doc Design Informatics Co Ltd, 2022) Tekinalp, Atakan; Kars, Taha Ulutan; Dikici, Hatice Zeynep; Demircioglu, Sinan; Ceneli, OzcanObjective: The study aims to determine the frequency and clinical features of COVID-19 during the long-term follow-up of patients with hematological malignancies. Methods: Patients with hematological malignancies followed in our center were evaluated retrospectively. The patients were divided into two groups with having COVID-19 between April 01, 2020, and July 01, 2021: those who had COVID-19 [COVID (+)] and those who didn't have COVID-19 [COVID (-)]. Results: 1258 patients were evaluated. Of these, 288 (22.9%) were found to have had COVID-19. The most common and least common diagnoses in the COVID (+) group were non-Hodgkin lymphoma (NHL) (21.7%) and Hodgkin lymphoma (HL) (6.9%), respectively. The malignancies with the highest and lowest rates of COVID-19 (+) were multiple myeloma (MM) (35.6%) and chronic myeloid leukemia (CML) patients (17.8%), respectively. The median age was higher in COVID (+) chronic lymphocytic leukemia (CLL) patients than in COVID (-) patients (73 vs. 66; p= 0.001). All deaths were due to COVID in COVID (+) patients. The mortality rate for all patients was found to be significantly higher in the COVID (+) group than in the COVID (-) group (22.8% vs. 11.9%; p<0.001). Myelodysplastic syndrome (MDS) (39.5%) and acute leukemia (AL) (35.7%) had the highest mortality rates in the COVID (+) group. The mortality rates in COVID (+) CLL (26% vs. 7%), AL (35.7% vs. 17.7%) and MM (28.6% vs. 9.2%) were significantly higher than in the COVID (-) group. There were no deaths due to COVID-19 in CML patients. 79.8% of COVID (+) patients were hospitalized, and the mortality rate in these patients was significantly higher than in outpatients (34.6% vs. 2.8%; p<0.001). The patients with the highest need for mechanic ventilation had MDS (44.8%) and AL (36%). Conclusion: Our study provides important data to the literature comparing the effect of SARS-CoV-2 on all hematological malignancies with malignant patients who do not have COVID-19.Öğe Might periostin serve as a marker of bone marrow involvement in patients with diffuse large B-cell lymphoma?(Walter De Gruyter Gmbh, 2022) Tekinalp, Atakan; Kars, Taha Ulutan; Tuna, Ali Kursat; Kilinc, Ibrahim; Demircioglu, Sinan; Ceneli, OzcanObjectives We measured the serum periostin levels in patients with DLBCL and determined whether the levels reflected the clinical findings. Methods This was a case-control study. DLBCL patients diagnosed between March 2021 and October 2021 (n=36) and healthy volunteers (n=36) (Control group) were included. The serum periostin levels of the two groups were compared. Moreover, subgroup analyses were conducted in the patient group. Results The serum periostin level was significantly higher in the patient than the control group (28.8 +/- 3.2 vs. 15.1 +/- 7.5 ng/mL, p=0.017). On subgroup analyses, the median serum periostin level of nine (25%) patients with bone marrow involvement was higher than that of the 27 (75%) lacking bone marrow involvement (12.7 vs. 21.7 ng/mL, p=0.018). On ROC analysis, the optimal periostin cutoff for bone marrow involvement was 17.3 ng/mL (sensitivity 77%, specificity 67%, AUC 0.765; 95% CI; 0.606-0.924, p=0.018). By the disease stage, the periostin level was higher in stage 4 patients than in those of other stages (21.3 vs. 12.0 ng/mL, p=0.029). Conclusions The periostin level correlated with such involvement; periostin may serve as a novel prognostic marker of DLBCL.Öğe Might periostin serve as a marker of bone marrow involvement in patients with diffuse large B-cell lymphoma?(Walter De Gruyter Gmbh, 2022) Tekinalp, Atakan; Kars, Taha Ulutan; Tuna, Ali Kursat; Kilinc, Ibrahim; Demircioglu, Sinan; Ceneli, OzcanObjectives We measured the serum periostin levels in patients with DLBCL and determined whether the levels reflected the clinical findings. Methods This was a case-control study. DLBCL patients diagnosed between March 2021 and October 2021 (n=36) and healthy volunteers (n=36) (Control group) were included. The serum periostin levels of the two groups were compared. Moreover, subgroup analyses were conducted in the patient group. Results The serum periostin level was significantly higher in the patient than the control group (28.8 +/- 3.2 vs. 15.1 +/- 7.5 ng/mL, p=0.017). On subgroup analyses, the median serum periostin level of nine (25%) patients with bone marrow involvement was higher than that of the 27 (75%) lacking bone marrow involvement (12.7 vs. 21.7 ng/mL, p=0.018). On ROC analysis, the optimal periostin cutoff for bone marrow involvement was 17.3 ng/mL (sensitivity 77%, specificity 67%, AUC 0.765; 95% CI; 0.606-0.924, p=0.018). By the disease stage, the periostin level was higher in stage 4 patients than in those of other stages (21.3 vs. 12.0 ng/mL, p=0.029). Conclusions The periostin level correlated with such involvement; periostin may serve as a novel prognostic marker of DLBCL.Öğe Pneumonitis associated with bortezomib in a patient with multiple myeloma(Sage Publications Ltd, 2023) Kars, Taha Ulutan; Yaskiran, Osman; Ceneli, OzcanIntroduction Bortezomib, which is widely used in the treatment of multiple myeloma (MM), is a proteasome inhibitor and acts by inducing apoptosis. Bortezomib has many side effects, mainly hematological, neurological, and gastrointestinal. A few cases of bortezomib-induced pneumonitis (BIP) have been reported in the literature. Case Report A 51-year-old male patient who was newly diagnosed with MM received bortezomib, cyclophosphamide, and dexamethasone as first-line therapy. In the first cycle, the patient developed dyspnea, tachypnea, and hypoxia after the fourth day of administration of bortezomib monotherapy according to the treatment protocol. Management and outcome Infection and pulmonary involvement of MM were excluded after radiological evaluations, and a diagnosis of BIP was made. Clinical control was achieved quickly with steroid therapy and oxygen support, and radiological findings improved with treatment. Due to this rare side effect of bortezomib, the treatment regimen containing bortezomib was changed. The patient is still receiving treatment that does not contain bortezomib and does not have any pulmonary problems. Discussion In cancer patients receiving treatment, infection and metastasis should be quickly ruled out when pulmonary problems occur, and drug-induced pneumonitis should be considered. This diagnosis, which often responds dramatically to steroids, has the potential to have serious consequences when not considered. In this case, we present bortezomib-associated pneumonitis, a rare side effect of bortezomib. The most important feature of this case is the development of this side effect at the beginning of the treatment, unlike other cases reported in the literature.Öğe Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma(Sage Publications Ltd, 2023) Kars, Taha Ulutan; Yorganci, Zahit Furkan; Yaskiran, Osman; Tekinalp, Atakan; Demircioglu, SinanIntroduction Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological. Rituximab may cause thrombocytopenia in the long term after administration. Rare cases of rituximab-induced acute thrombocytopenia have been reported in the literature. Case Report A 51-year-old female patient who was newly diagnosed with splenic marginal zone lymphoma received rituximab as first-line therapy. Petechiae occurred in the lower extremities on the day following rituximab administration. The blood test showed a severe drop in the platelet count from 112,000/mu L to 5000/mu L. Blood peripheral smear evaluation confirmed severe thrombocytopenia. Management and outcome There was no change in hemoglobin or white blood cell levels. After the diagnosis of rituximab-induced acute thrombocytopenia, thrombocyte suspension was administered due to the risk of bleeding. Close clinical and laboratory observations were made. The platelet count began to rise gradually in the following period. Before the second week of rituximab administration, the platelet count was 122,000/mu L. No complications developed after premedication and slow rituximab administration, and subsequent treatments were continued in the same way. Discussion Rituximab has widespread use, especially in malignancies and autoimmune diseases. Like many monoclonal antibodies, rituximab has several side effects. Thrombocytopenia is a long-term side effect associated with rituximab, and rituximab-induced severe acute thrombocytopenia has been rarely reported. Therefore, it should be kept in mind that severe acute thrombocytopenia may develop after rituximab administration.Öğe Yeni tanı tiroid kanserli hastalarda serum osteopontin düzeyleri(Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi, 2017) Kars, Taha Ulutan; Kulaksızoğlu, MustafaTiroid kanseri endokrin sistemin en sık görülen kanseridir. Osteopontin, osteoblast diferansiyasyonunda ve kemik formasyonunda rol alan bir glikoproteindir. Osteopontin, hücre migrasyonu ve hücre yaşamının devamında rol almakla birlikte osteopontinin tümörogenezis ve invazyon ile de ilişkisi bilinmektedir. Osteopontin düzeyleri bir çok malignitede yüksek saptanmıştır. Yeni tanı alan tiroid kanserli hastaların serum osteopontin düzeylerinin belirlenmesi, bunların sağlıklı kontrollerin serum osteopontin düzeyleri ile karşılaştırılması ve tiroid kanserli hastalarda bu düzeylerin prognoz ve agresiflik ile ilişkisinin araştırılması amacıyla bu çalışma planlanmıştır. Yöntem: Mayıs 2016-Nisan 2017 arasındaki bir yıllık süreçte araştırma grubu için tiroid kanseri tanısı almış 40 hasta, kontrol grubu için 40 katılımcı olmak üzere toplam 80 kişi dahil edilmiş, bu kişilerden sabah açlıkta 5 ml venöz kan alınmış, NEÜ Meram Tıp Fakültesi Tıbbi Biyokimya A.B.D. Laboratuvarı'nda santrifüj edilmiş ve serum örneği işleme konulacağı zamana kadar -80 ºC'de saklanmıştır. Tüm örnekler toplandıktan sonra aynı günde ELISA yöntemi ile serum osteopontin düzeyleri çalışılmıştır. Bulgular: Hasta ve kontrol grubunun serum osteopontin düzeyleri sırası ile 10,21 ± 3,67 ng/mL ve 6,14 ± 2,29 ng/mL olarak saptanmıştır. Hasta grubunda osteopontin düzeyleri daha yüksek görülmüştür ve istatistiksel olarak anlamlı fark bulunmuştur (p<0,001). Çalışmamızda osteopontin ile prognoz ve agresiflik arasında anlamlı fark saptanmamıştır. Sonuç: Tiroid kanserli hastalarda serum osteopontin düzeyleri kontrollere göre daha yüksek olarak saptandı. Bu durum osteopontinin, tümör gelişiminde rolü olabileceğini gösteriyor olabilir. Prognoz belirleme ve agresiflik tayininde ise anlamlı ilişki saptanmadı. Osteopontinin tiroid kanser gelişiminde ve prognozunda ilişkisini belirlemek için hasta sayısının daha fazla ve tümör evresinin daha ileri olduğu çalışmalar yapılmasının literatüre katkısı olacağı düşüncesindeyiz. Anahtar kelimeler: Tiroid kanseri, osteopontin
